propodine
dechra regulatory -
propomitor
orion corporation orionintie 1 fi -
sevofluran piramal 250 ml para za inhaliranje, tekočina
sevofluran - para za inhaliranje, tekočina - sevofluran 250 ml / 1 ml - sevofluran
flukonazol vitabalans 150 mg tablete
flukonazol - tableta - flukonazol 150 mg / 1 tableta - flukonazol
flukonazol vitabalans 150 mg tablete
flukonazol - tableta - flukonazol 150 mg / 1 tableta - flukonazol
akynzeo
helsinn birex pharmaceuticals ltd - netupitant, palonosetron hidroklorid - vomiting; neoplasms; nausea; cancer - antiemetics in antinauseants, - akynzeo je navedeno v odraslim za:preprečevanje akutne in zapoznele slabost in bruhanja, povezanih z močno emetogenic cisplatin, ki temelji kemoterapijo raka. preprečevanje akutne in zapoznele slabost in bruhanja, povezanih z zmerno emetogenic kemoterapijo raka.
cresemba
basilea pharmaceutica deutschland gmbh - isavukonazol - aspergiloza - cresemba je navedeno pri odraslih za zdravljenje:invazivne aspergillosismucormycosis pri bolnikih, za katere amphotericin b je inappropriateconsideration treba uradna smernice za ustrezno uporabo protiglivično agenti.
ivemend
merck sharp & dohme b.v. - fosaprepitant - vomiting; cancer - antiemetics in antinauseants, - preprečevanje slabosti in bruhanja, povezanih z močno in zmerno emetogenic kemoterapijo raka pri odraslih in pediatričnih bolnikih, starih 6 mesecev in več. ivemend 150 mg je podana kot del kombiniranega zdravljenja.
aprepitant teva 125 mg in 80 mg trde kapsule
aprepitant - kapsula, trda - aprepitant 125 mg / 1 kapsula - aprepitant
lorviqua
pfizer europe ma eeig - lorlatinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.